Results 41 to 50 of about 2,175,372 (155)

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells

Scientific Reports, 2022
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Lenvatinib is approved as a first-line treatment for unresectable HCC.
Xiaoping He, Yohko Hikiba, Yoshimasa Suzuki, Yoshinori Nakamori, Yushi Kanemaru, Makoto Sugimori, Takeshi Sato, Akito Nozaki, Makoto Chuma, Shin Maeda   +9 more
doaj   +1 more source

Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction [PDF]

Background: Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has an anticancer action in patients with differentiated thyroid cancer that is refractory to radioiodine.
2191, 藤原, 和典, 福原, 隆宏, フクハラ, タカヒロ, 26631, キタノ, ヒロヤ, フジワラ, カズノリ, 小山, 哲史, コヤマ, サトシ, Morisaki, Tsuyoshi, 三宅, 成智, 100001499, 100002206, 26630, Koyama, Satoshi, 3674, 80403418, 40197273, 90403419, 100001318, 4942, 26629, Fujiwara, Kazunori, Fukuhara, Takahiro, Miyake, Naritomo, Takeuchi, Hiromi, Kitano, Hiroya, ミヤケ, ナリトモ, 60464278, タケウチ, ヒロミ, 竹内, 裕美, 100000179, 369, 405, 100000417   +34 more
core   +2 more sources

DataSheet_1_Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma.zip

, 2022
Lenvatinib is the first-line treatment for hepatocellular carcinoma (HCC), the most common type of primary liver cancer; however, some patients become refractory to lenvatinib.
Juan Liu (6492), Dawei Sun (13450), Jiahong Dong (315208), Yunfang Wang (234027)   +3 more
core   +1 more source

Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway

Pharmacological Research
Lenvatinib is a frontline tyrosine kinase inhibitor for patients with advanced hepatocellular carcinoma (HCC). However, just 25% of patients benefit from the treatment, and acquired resistance always develops.
Yilan Huang, Siwei Wang, Xiaojun Zhang, Chen Yang, Sikai Wang, Hongxia Cheng, Aiwu Ke, Chao Gao, Kun Guo   +8 more
doaj   +1 more source

Overexpression of the lncRNA HOTAIRM1 promotes lenvatinib resistance by downregulating miR-34a and activating autophagy in hepatocellular carcinoma

Discover Oncology, 2023
Background Hepatocellular carcinoma (HCC) is one of the most common malignant cancers in humans and has a high fatality rate. Despite pharmacological advances such as sorafenib and lenvatinib approval, responses are seen only in a limited fraction of ...
Danyan Gu, Meng Tong, Jing Wang, Bocheng Zhang, Jinghua Liu, Guoqiang Song, Biao Zhu   +6 more
doaj   +1 more source

Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma

Frontiers in Oncology, 2022
Lenvatinib is the first-line treatment for hepatocellular carcinoma (HCC), the most common type of primary liver cancer; however, some patients become refractory to lenvatinib.
Dawei Sun, Juan Liu, Juan Liu, Yunfang Wang, Yunfang Wang, Jiahong Dong, Jiahong Dong, Jiahong Dong   +7 more
doaj   +1 more source

Exosome-derived hsa_circ_0007132 promotes lenvatinib resistance by inhibiting the ubiquitin-mediated degradation of NONO. [PDF]

Noncoding RNA Res
Hepatocellular carcinoma (HCC) is a highly heterogeneous solid tumor, with its incidence showing a troubling upward trend over the past decade. Lenvatinib is one of the first-line medications for treating advanced HCC, however, the development of ...
Cao M, Li Y, Su X, Tang Y, Yuan F, Ren Y, Deng M, Yao Z.   +7 more
europepmc   +2 more sources

AL398, A Novel NSUN6 Inhibitor, Attenuates Epithelial‐Mesenchymal Transition and Metastasis in Endometrial Cancer by Abrogating m5C‐Dependent Stabilization of Snail mRNA

Advanced Science, EarlyView.
Proposed molecular mechanism: NSUN6 catalyzes m5C methylation on Snail mRNA to enhance its stability, leading to Snail upregulation and EMT promotion. The first‐in‐class inhibitor AL398 suppresses endometrial cancer metastasis by targeting the NSUN6‐m5C‐Snail. axis. ABSTRACT Endometrial cancer (EC) constitutes a leading gynecologic malignancy for which
Xiangzhuan Zhao, Linlin Yang, Huanxiang Chen, Chenfeng Guo, Hongshen Lu, Ying Zhu, Xuanzhi Wang, Yang Li, Ruike Zhang, Zichong Huang, Yifang Chen, Keyu Jin, Zeduo Xu, Lingxiu Meng, Longfeng Zhang, Yuanyuan Han, Yicong Yan, Qiaozhen Kang, Junhu Wan, Hongyang Liu   +19 more
wiley   +1 more source

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

Advanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert, Christophe Nguyen, Sean Edward Dunn, Magali Gary‐Bobo, Jérôme Lacombe, Justin Moser, Frédéric Zenhausern, Jean‐Olivier Durand, Frédérique Cunin   +8 more
wiley   +1 more source

USP4‐Dependent CHAF1B Stabilization Regulates Distinct SETDB1 Ubiquitin States Linked to AKT T308 Signaling and Lipogenic Remodeling in HCC

Advanced Science, EarlyView.
USP4 stabilizes CHAF1B by limiting K48‐linked ubiquitination. Stabilized CHAF1B supports UHRF1‐associated K63‐linked SETDB1 ubiquitination and cytoplasmic redistribution, whereas CHAF1B loss favors VHL‐dependent K11‐associated degradative ubiquitination and proteasomal loss of SETDB1.
Saiyan Bian, Yun Tong, Wenkai Ni, Zhangzhi Tang, Weiting Chen, Kexin Ma, Lihan Jiang, Jiayu Shao, Xuyang He, Wenjie Zheng   +9 more
wiley   +1 more source